Key Drivers
- Sharp debt increase
- Negative cash flow
- Strong liquidity
AIAI Summary
INBX has shifted from a long‑dated R&D optionality play into a binary, near‑term, event‑driven investment where ozekibart's BLA outcome and the company's ability to secure commercialization/partnering or fresh capital will largely determine valuation—monitor BLA progress, cash burn versus runway, and any partner/debt developments as immediate actionable triggers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Sharp debt increase
- •Negative cash flow
- •Strong liquidity
INBX swung from a large reported FY2024 profit to a Q3 2025 operating loss and negative EPS, with strong cash/current ratio offset by sharply higher debt, negative operating cash flow, and declining book value—raising serious solvency and profitability concerns.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support-tested rebound
- •Lower-highs series
INBX is in a short-term downtrend below its last month moving average with bearish-but-not-oversold momentum, sitting on $68–$70 support that, if decisively broken, signals a likely extension toward lower levels while reclaiming ~$78–$80/80–82 would negate the downside bias.
Series of lower highs since mid‑February with average daily losses exceeding gains, signaling increased downside pressure
Sentiment & News
Key News Insights:
- •Large stake reduction
- •ESMO data presentation
- •Phase 1 momentum
Inhibrx: a major investor cut its stake by 54.9% while the company advances clinical exposure with a Phase 1 ozekibart combination data presentation at ESMO, highlighting investor reallocation amid ongoing pipeline momentum.
The investor exit may weigh on near-term sentiment, but the ESMO presentation could sustain scientific credibility and longer-term pipeline interest
Similar Companies in Healthcare
Other companies in the same sector with AI ratings